- Home
- COOK vs NGNE Comparison
COOK vs NGNE Comparison
Compare COOK & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOK
- NGNE
- Stock Information
- Founded
- COOK 1985
- NGNE 2003
- Country
- COOK United States
- NGNE United States
- Employees
- COOK N/A
- NGNE N/A
- Industry
- COOK Wholesale Distributors
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- COOK Consumer Discretionary
- NGNE Health Care
- Exchange
- COOK Nasdaq
- NGNE Nasdaq
- Market Cap
- COOK 255.1M
- NGNE 213.2M
- IPO Year
- COOK 2021
- NGNE N/A
- Fundamental
- Price
- COOK $1.96
- NGNE $21.94
- Analyst Decision
- COOK Buy
- NGNE Strong Buy
- Analyst Count
- COOK 7
- NGNE 7
- Target Price
- COOK $2.43
- NGNE $41.86
- AVG Volume (30 Days)
- COOK 318.2K
- NGNE 222.5K
- Earning Date
- COOK 08-05-2025
- NGNE 08-08-2025
- Dividend Yield
- COOK N/A
- NGNE N/A
- EPS Growth
- COOK N/A
- NGNE N/A
- EPS
- COOK N/A
- NGNE N/A
- Revenue
- COOK $602,441,000.00
- NGNE $925,000.00
- Revenue This Year
- COOK $0.06
- NGNE N/A
- Revenue Next Year
- COOK $3.18
- NGNE N/A
- P/E Ratio
- COOK N/A
- NGNE N/A
- Revenue Growth
- COOK 0.80
- NGNE N/A
- 52 Week Low
- COOK $1.28
- NGNE $6.88
- 52 Week High
- COOK $3.97
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- COOK 61.44
- NGNE 62.83
- Support Level
- COOK $1.85
- NGNE $19.01
- Resistance Level
- COOK $1.98
- NGNE $18.21
- Average True Range (ATR)
- COOK 0.10
- NGNE 1.65
- MACD
- COOK 0.01
- NGNE 0.41
- Stochastic Oscillator
- COOK 75.14
- NGNE 96.68
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.